Kastinen, M., Sirniö, P., Elomaa, H. et al. Immunological and prognostic significance of tumour necrosis in colorectal cancer. Br J Cancer 128, 2218–2226 (2023). https://doi.org/10.1038/s41416-023-02258-2
Immunological and prognostic significance of tumour necrosis in colorectal cancer
|Author:||Kastinen, Meeri1; Sirniö, Päivi1; Elomaa, Hanna2,3;|
1Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland
2Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland
3Department of Education and Research, Wellbeing services county of Central Finland, Jyväskylä, Finland
4Department of Pathology, Wellbeing services county of Central Finland, Jyväskylä, Finland
5Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
6Research Unit of Biomedicine, Medical Research Center Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland
7Department of Pediatric Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland
8Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland
9Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, Tampere, Finland
10Department of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
11Applied Tumor Genomics, Research Program Unit, University of Helsinki, Helsinki, Finland
12Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland
|Online Access:||PDF Full Text (PDF, 0.9 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe20231106143264
|Publish Date:|| 2023-11-06
Background: Colorectal cancer (CRC) causes the second most cancer deaths worldwide, but the disease course varies according to tumour characteristics and immunological factors. Our objective was to examine the associations of tumour necrosis with tumour characteristics, immune cell infiltrates, serum cytokine concentrations, as well as prognosis in CRC.
Methods: Three independent CRC cohorts, including 1413 patients, were analysed. Associations of the areal percentage of tumour necrosis with clinicopathologic parameters, tumour infiltrating immune cells, cytokine concentrations in systemic and mesenteric vein blood, and survival were examined.
Results: Higher tumour necrosis percentage associated with shorter colorectal cancer-specific survival independent of tumour grade, T, N or M-class, mismatch repair status, BRAF status, and other possible confounding factors. In the largest cohort (N = 1100), the HR for high tumour necrosis percentage (≥40% vs. <3%) was 3.22 (95% CI 1.68–6.17, Ptrend < 0.0001). Tumour necrosis percentage positively correlated with peripheral serum levels of CXCL8, a proinflammatory chemokine, and negatively correlated with mesenteric serum levels of CXCL10 and mast cell densities in the invasive margin of the tumour.
Conclusions: Our results support the value of tumour necrosis as a prognostic factor in colorectal cancer. CXCL8 may have a role in the systemic effects of tumour necrosis.
British journal of cancer
|Pages:||2218 - 2226|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This study was funded by Cancer Foundation Finland (59-5619 to JPV). Open Access funding provided by University of Oulu including Oulu University Hospital.
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.